Literature DB >> 17418635

PPARgamma in immunity and inflammation: cell types and diseases.

Lajos Széles1, Dániel Töröcsik, László Nagy.   

Abstract

The lipid activated transcription factor, PPARgamma appears to have multiple functions in the immune system. There are several cell types expressing the receptor, most prominently antigen presenting cells, such as macrophages and dendritic cells. The receptor's activation leads to primary transcriptional activation of many, mostly lipid metabolism-related genes. However, gene regulation also occurs on immunity and inflammation-related genes. Key questions are: in what way lipid metabolism and immune regulation are connected and how activation and/or repression of gene expression may modulate inflammatory and anti-inflammatory responses and in what way can these be utilized in therapy. Here we provide a cell type and disease centric review on the role of this lipid activated transcription factor in the various cells of the immune system it is expressed in, and in some major inflammatory diseases such as atherosclerosis, inflammatory bowel disease and rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418635     DOI: 10.1016/j.bbalip.2007.02.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  65 in total

1.  Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency.

Authors:  Philippe M Campeau; Olga Astapova; Rebecca Martins; Jean Bergeron; Patrick Couture; Robert A Hegele; Todd Leff; Claude Gagné
Journal:  J Lipid Res       Date:  2012-07-02       Impact factor: 5.922

2.  Type 1 and type 2 diabetes-chalk and cheese?

Authors:  K R Owen; M I McCarthy
Journal:  Diabetologia       Date:  2009-08-01       Impact factor: 10.122

3.  Agonistic induction of PPARγ reverses cigarette smoke-induced emphysema.

Authors:  Ming Shan; Ran You; Xiaoyi Yuan; Michael V Frazier; Paul Porter; Alexander Seryshev; Jeong-Soo Hong; Li-zhen Song; Yiqun Zhang; Susan Hilsenbeck; Lawrence Whitehead; Nazanin Zarinkamar; Sarah Perusich; David B Corry; Farrah Kheradmand
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

4.  Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma.

Authors:  Nicholas P Evans; Sarah A Misyak; Eva M Schmelz; Amir J Guri; Raquel Hontecillas; Josep Bassaganya-Riera
Journal:  J Nutr       Date:  2010-01-20       Impact factor: 4.798

Review 5.  Peroxisome proliferator-activated receptor (PPAR): balance for survival in parasitic infections.

Authors:  Marion M Chan; Kyle W Evans; Andrea R Moore; Dunne Fong
Journal:  J Biomed Biotechnol       Date:  2010-02-10

6.  PPAR-γ and Akt regulate GLUT1 and GLUT3 surface localization during Mycobacterium tuberculosis infection.

Authors:  Shyamashree Dasgupta; Ramesh Chandra Rai
Journal:  Mol Cell Biochem       Date:  2017-08-29       Impact factor: 3.396

7.  MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.

Authors:  Francine M Gregoire; Fang Zhang; Holly J Clarke; Thomas A Gustafson; Dorothy D Sears; Svetlana Favelyukis; James Lenhard; Dennis Rentzeperis; L Edward Clemens; Yi Mu; Brian E Lavan
Journal:  Mol Endocrinol       Date:  2009-04-23

8.  Regulation of Translational Efficiency by Disparate 5' UTRs of PPARgamma Splice Variants.

Authors:  Shawn McClelland; Roopali Shrivastava; Jheem D Medh
Journal:  PPAR Res       Date:  2009-11-23       Impact factor: 4.964

9.  No association of multiple type 2 diabetes loci with type 1 diabetes.

Authors:  S M Raj; J M M Howson; N M Walker; J D Cooper; D J Smyth; S F Field; H E Stevens; J A Todd
Journal:  Diabetologia       Date:  2009-05-20       Impact factor: 10.122

10.  Effects of 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) and rosiglitazone on human gammadelta2 T cells.

Authors:  Haishan Li; C David Pauza
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.